1. Home
  2. DINO vs HALO Comparison

DINO vs HALO Comparison

Compare DINO & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HF Sinclair Corporation

DINO

HF Sinclair Corporation

HOLD

Current Price

$125.64

Market Cap

12.9B

Sector

Energy

ML Signal

HOLD

Logo Halozyme Therapeutics Inc.

HALO

Halozyme Therapeutics Inc.

HOLD

Current Price

$123.99

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DINO
HALO
Founded
1947
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9B
12.0B
IPO Year
2022
2001

Fundamental Metrics

Financial Performance
Metric
DINO
HALO
Price
$125.64
$123.99
Analyst Decision
Hold
Buy
Analyst Count
16
9
Target Price
★ $116.80
$108.78
AVG Volume (30 Days)
★ 2.3M
2.2M
Earning Date
10-28-2026
11-02-2026
Dividend Yield
★ 1.69%
N/A
EPS Growth
★ 238.46
N/A
EPS
★ 8.48
3.11
Revenue
N/A
★ $151,862,000.00
Revenue This Year
$31.11
$34.69
Revenue Next Year
N/A
$11.65
P/E Ratio
★ $14.88
$39.59
Revenue Growth
N/A
N/A
52 Week Low
$45.71
$61.23
52 Week High
$129.37
$123.51

Technical Indicators

Market Signals
Indicator
DINO
HALO
Relative Strength Index (RSI) 72.24 71.47
Support Level $103.00 $105.27
Resistance Level N/A N/A
Average True Range (ATR) 3.73 3.39
MACD 0.70 1.05
Stochastic Oscillator 87.05 97.60

Price Performance

Historical Comparison
DINO
HALO

About DINO HF Sinclair Corporation

HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 350 distributors and 1,700 wholesale branded sites across 30 states. It also owns and operates 4,500 miles of petroleum product pipelines and terminals principally in the southwestern United States.

About HALO Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Share on Social Networks: